Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

NCT07280013 is registered in ClinicalTrials.gov with C4 Therapeutics, Inc. as lead sponsor.

NCT NCT07280013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07280013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Lead sponsor
C4 Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 6, 2026
Completion date
June 30, 2029
Enrollment
60 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma (mm)